Tin tức & Cập nhật

Rheumatoid arthritis: Another reason to be wary of long-term PPI use?

15 Jul 2020 bởi

Regular users of proton pump inhibitors (PPIs) risk developing rheumatoid arthritis, and the risk increases proportionally with the duration of use, according to a study.

Rheumatoid arthritis: Another reason to be wary of long-term PPI use?

15 Jul 2020

Original New Drug Application Approvals by US FDA (01 - 15 July 2020)

15 Jul 2020

New drug applications approved by US FDA as of 01 - 15 July 2020 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (01 - 15 July 2020)

15 Jul 2020

Tanezumab reduces pain intensity, improves daily function in patients with chronic low back pain

15 Jul 2020 bởi

Treatment with tanezumab, a monoclonal antibody against nerve growth factor, significantly reduces pain intensity and improves daily function in patients with chronic low back pain, according to a trial presented at EULAR 2020.

Tanezumab reduces pain intensity, improves daily function in patients with chronic low back pain

15 Jul 2020

For patients with rheumatoid arthritis, diets matter

14 Jul 2020 bởi

Foods factor in the management of symptoms of rheumatoid arthritis (RA), and several dietary approaches help by removing staples that promote inflammation or by adding more of anti-inflammatory edibles and altering the gut microbiota, according to a team of researchers.

For patients with rheumatoid arthritis, diets matter

14 Jul 2020

Glucocorticoid users risk developing hypertension

14 Jul 2020

Use of glucocorticoid at doses ≥7.5 mg poses an increased risk of incident hypertension among patients with rheumatoid arthritis, a study has found.

Glucocorticoid users risk developing hypertension

14 Jul 2020

Netakimab improves treatment outcomes in PsA

09 Jul 2020 bởi

The anti-interleukin 17A antibody netakimab reduces disease activity and skin manifestations in patients with active psoriatic arthritis (PsA), consequently improving patient-reported outcomes (PROs), analyses of the phase III PATERA trial have shown.

Netakimab improves treatment outcomes in PsA

09 Jul 2020

Novel JAK1 inhibitor on par with adalimumab in RA over 52 weeks

08 Jul 2020 bởi

The investigational JAK1* inhibitor filgotinib was noninferior to adalimumab in reducing disease activity in patients with moderate-to-severe rheumatoid arthritis (RA) who had inadequate response to methotrexate (MTX-IR), according to the FINCH 1 study presented at EULAR 2020 Virtual Meeting.

Novel JAK1 inhibitor on par with adalimumab in RA over 52 weeks

08 Jul 2020

SELECT-PsA-1 demos upadacitinib benefits in psoriatic arthritis

08 Jul 2020 bởi

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.

SELECT-PsA-1 demos upadacitinib benefits in psoriatic arthritis

08 Jul 2020

Vitamin D, fish oil supplementation of no benefit to adults with chronic knee pain

08 Jul 2020

Long-term supplementation of vitamin D and marine omega‐3 fatty acids in adults with chronic knee pain turns out to be fruitless, yielding no favourable effect on knee pain, function, or stiffness, as shown in a study.

Vitamin D, fish oil supplementation of no benefit to adults with chronic knee pain

08 Jul 2020

Is ticagrelor protective against osteoarthritis too?

08 Jul 2020 bởi

Ticagrelor reduces the risk of developing osteoarthritis by about 30 percent compared with another antiplatelet, clopidogrel, as shown in a recent study.

Is ticagrelor protective against osteoarthritis too?

08 Jul 2020

Tin tức & Cập nhật

Lọc theo Chuyên ngành:

Chuyên ngành:

Rheumatoid arthritis: Another reason to be wary of long-term PPI use?

Rheumatoid arthritis: Another reason to be wary of long-term PPI use?

Original New Drug Application Approvals by US FDA (01 - 15 July 2020)

Original New Drug Application Approvals by US FDA (01 - 15 July 2020)

Tanezumab reduces pain intensity, improves daily function in patients with chronic low back pain

Tanezumab reduces pain intensity, improves daily function in patients with chronic low back pain

For patients with rheumatoid arthritis, diets matter

For patients with rheumatoid arthritis, diets matter

Glucocorticoid users risk developing hypertension

Glucocorticoid users risk developing hypertension

Netakimab improves treatment outcomes in PsA

Netakimab improves treatment outcomes in PsA

Novel JAK1 inhibitor on par with adalimumab in RA over 52 weeks

Novel JAK1 inhibitor on par with adalimumab in RA over 52 weeks

SELECT-PsA-1 demos upadacitinib benefits in psoriatic arthritis

SELECT-PsA-1 demos upadacitinib benefits in psoriatic arthritis

Vitamin D, fish oil supplementation of no benefit to adults with chronic knee pain

Vitamin D, fish oil supplementation of no benefit to adults with chronic knee pain

Is ticagrelor protective against osteoarthritis too?

Is ticagrelor protective against osteoarthritis too?